Entzug ohne Entzugserscheinungen! DTOX - 500 Beiträge pro Seite

[morchel]

July 16, 2002 07:31

CITA Biomedical`s Proprietary Program to End Cocaine Dependence Used To Successfully Treat First U.S. Patient for Cocaine Addiction
Jump to first matched term

Patient Had No Withdrawal Symptoms and After Treatment No Cravings for Alcohol or Cocaine

BEVERLY HILLS, Calif., July 16 /PRNewswire-FirstCall/ -- CITA Biomedical, Inc. (OTC Bulletin Board: DTOX) a growing leader in the treatment of substance dependency, today announced that the first U.S. Detoxification and NeuroAdaptation (DNA) for Cocaine patient was successfully treated for cocaine dependence. DNA for Cocaine is a part of a family of treatments called DNA for Addictions. The DNA for Addictions treatment family includes DNA for Alcohol, DNA for Cocaine, DNA for Alcohol and Cocaine, and DNA for Crack Cocaine. CITA has patents pending for the family of DNA treatments.

(Photo: http://www.newscom.com/cgi-bin/prnh/19990413/LAPHOTO )

The patient, a 35-year-old male first used marijuana and alcohol at age 15. At age 17 he was free-basing which eventually turned into a $2000 a week cocaine and crack cocaine habit, including the consumption of a fifth of alcohol or two six-packs of beer daily plus marijuana use. "I`ve probably tried 20 or more programs including residential, in-patient, out-patient, AA, and NA," said the patient. "There are a lot of advantages to DNA but the biggest advantage is that you don`t even think of alcohol or cocaine! You don`t crave it. You just don`t think about it! I`ve tried to quit in the past but it never worked out until now." The treatment was administered to the patient for less than an hour daily over three consecutive days. The patient experienced no symptoms of withdrawal.

DNA for Cocaine establishes a new treatment regimen in the fight against cocaine addiction, a disorder that impedes normal neural functioning of the brain and body systems as a whole. Cocaine addiction causes cravings, possible brain damage, and can lead to potentially life-threatening withdrawal symptoms. Historically, the disorder of cocaine addiction has been treated only through behavioral intervention, but the CITA DNA treatment provides a solution for treating both the physiological and psychological components of this devastating condition.

The patients that were treated in Europe last year experienced a less than 25 percent relapse rate, compared to a more than 75 percent relapse rate generally associated other accepted means of treating cocaine addiction. The new treatment was also shown to reduce the time, pain, and costs associated with withdrawal, and allowed the patients to return to a productive level of functioning within hours of the treatment`s completion.

"We are pleased to begin another proven safe and effective DNA for addictions treatment in the U.S. We anticipate that this patient will be the first of thousands that we will treat for alcohol and cocaine dependence in the coming year," said Joseph Dunn, president and CEO of CITA Biomedical. "DNA took years to develop and continues to be extremely successful in Europe with our CITA affiliate. CITA is pleased to finally help address the devastation to society caused by cocaine and crack cocaine dependence."

About CITA Biomedical, Inc.

CITA Biomedical, Inc., headquartered in Beverly Hills, Calif., focuses on the innovative treatment of addiction. The company holds the U.S. patent for its successful UROD (Ultra Rapid Opiate Detoxification) treatment method. UROD is the only clinically tested and effective treatment method to rapidly detoxify individuals addicted to opiate-based drugs, including heroin within four to six hours with few, if any, withdrawal symptoms. The company recently announced a new family of revolutionary treatments, Detoxification and NeuroAdaptation (DNA) for Addictions. The first treatments from this family treat cocaine, cocaine, and poly-drug addictions. To date CITA has grown its business through internal expansion and now seeks compatible, leading, and complementing technologies and acquisitions to enhance its corporate portfolio. CITA Biomedical, Inc. has two operating divisions CITA Americas, Inc., and AltTPro, Inc. For more information, please visit www.citabio.com

UROD is a registered trademark of CITA Biomedical, Inc.

The information contained in this press release includes forward-looking statements. Forward-looking statements include declarations concerning plans, objectives, goals, strategies, future events and/or performance, and underlying assumptions and other statements which are other than statements of historical facts. Forward-looking statements usually contain the words "estimate," "anticipate," "believe," "expect" and other similar expressions that involve risks and uncertainties. These risks and uncertainties include, but are not limited to, the Company`s status as a start-up enterprise with uncertain profitability, its need for significant capital, limited facilities, competition, uncertainty as to market acceptance of its services, and the protection of its intellectual property. The Company`s actual results could differ materially from those expressed or implied in any forward-looking statements.

For further information please contact: Judy Ryon of CITA Biomedical, Inc., [phone], [e-mail]; or Laurel Moody of Vision Corporate Consulting, [phone], [e-mail], for CITA Biomedical, Inc.

MAKE YOUR OPINION COUNT - Click Here http://tbutton.prnewswire.com/prn/11690X01168831

SOURCE CITA Biomedical, Inc.

/CONTACT: Judy Ryon of CITA Biomedical, Inc., [phone],
[e-mail]; or Laurel Moody of Vision Corporate Consulting,
[phone], [e-mail], for CITA Biomedical, Inc./

/Photo: http://www.newscom.com/cgi-bin/prnh/19990413/LAPHOTO

PRN Photo Desk, 888-776-6555 or 212-782-2840/

/Web site: http://www.citabio.com /


morchel

[loss_pro]

die hatten vor ein paar tagen das gleiche für alkoholkonsum gemeldet, stiegen aber unter geringem volumen nur von 6 auf 8 cents, war selbst dabei, wäre aber sehr vorsichtig, super illiquide! und wirft doch einige fragen auf FDA etc.

[morchel]

Loss-pro du alter OTC Zocker, warum lässt du uns an solchen Chancen nicht teilhaben?

da hätten ja wesentlich mehr daran verdienen können!


Aber du hast recht. Die FDA wird da noch ein wörtchen mitreden!

morchel

[loss_pro]

hätte ich gemacht, nur nachdem der umsatz nach meinem kauf direkt zur eröffnung doch sehr (sehr!) bescheiden blieb (bei so einer interessanten meldung +2mio mcap), kam mir das doch verdächtig vor; hatte mich schon gewundert, daß ich überhaupt zu .06 zum zuge kam. hab nach ein paar stunden immerhin mit einem cent gewinn verkauft.

[morchel]

den Umsatz kann man eben nicht voraussagen. relativ sicher reagieren Aktien die ohnehin sehr populär sind!

z.b. FONX ECNC oder dergleichen!

morchel

[spirity]

@ morchel

Wo kann man den CITA Biomedical, Inc. (OTC Bulletin Board: DTOX) von Deutschland aus handeln?

Vielleicht doch eine Chance?

Danke.

spirity

[spirity]

Weiß jemand mehr zu CITA Biomedical?

http://biz.yahoo.com/prnews/020917/latu056_1.html


Press Release Source: CITA Biomedical, Inc.


CITA Biomedical Licenses Innovative Treatments for Alcohol, Cocaine, and Crack Dependence to Major California Medical Center
Freedom Treatment Center Treating Patients Successfully Since Early July
Tuesday September 17, 7:31 am ET


BEVERLY HILLS, Calif., Sept. 17 /PRNewswire-FirstCall/ -- CITA Biomedical, Inc. (OTC Bulletin Board: DTOX - News) a growing leader in the treatment of addiction dependency, today announced that it has signed a license agreement with Freedom Treatment Center in Southern California. The agreement enables Freedom Treatment Center to provide CITA`s Detoxification and NeuroAdaptation (DNA) for Addictions family of treatments. Freedom Treatment Center has been successfully treating patients with DNA for Addictions since early July. The DNA for Addictions treatment family includes DNA for Alcohol, DNA for Alcohol and Cocaine, DNA for Cocaine, and DNA for Crack Cocaine. CITA has patents pending for the family of DNA treatments.
(Photo: http://www.newscom.com/cgi-bin/prnh/19990413/LAPHOTO )
"DNA for Addictions family of treatments is an important option for our patients and community," said Dr. Morris Loffman, neurosurgeon and managing partner of Freedom Treatment Center. "Because this is the only service of its kind in this area, our community now has the most advanced and effective treatment options available to them. More important, the service is provided in a medical center setting and safely administered by Freedom`s staff of very experienced doctors."

DNA for Addictions establishes a new treatment regimen in the fight against drug addiction, a disorder that impedes normal neural functioning of the brain and body systems as a whole. Addiction causes cravings, possible brain damage, and can lead to potentially life-threatening withdrawal symptoms. Historically, the disorder of addiction has been treated only through behavioral intervention, but the CITA DNA treatment provides a solution for treating both the physiological and psychological components of this devastating disease.

DNA for Addictions patients experience a less than 25 percent relapse rate, compared to a more than 75 percent relapse rate generally associated other accepted means of treating addiction. The new treatment was also shown to reduce the time, pain, and costs associated with withdrawal, and allowed the patients to return to a productive level of functioning within hours of the treatment`s completion.

"We are pleased to be working with Freedom Treatment Center and its highly competent medical staff, to provide the DNA for Addictions family of treatments to their community," said Joseph Dunn, president and CEO of CITA Biomedical. "Treating both the physical and psychological components of addiction are key to DNA for Addictions` success and what sets DNA apart from other treatments. By working together, CITA and Freedom Treatment Center are able to offer high quality, safe, and cost effective addiction treatment services."

About CITA Biomedical, Inc.

CITA Biomedical, Inc., headquartered in Beverly Hills, Calif., focuses on the innovative treatment of addiction. The company holds the U.S. patent for its successful UROD (Ultra Rapid Opiate Detoxification) treatment method. UROD is the only clinically tested and effective treatment method to rapidly detoxify individuals addicted to opiate-based drugs, including heroin within four to six hours with few, if any, withdrawal symptoms. The company recently announced a new family of revolutionary treatments, Detoxification and NeuroAdaptation (DNA) for Addictions. The first treatments from this family treat alcohol, cocaine, and poly-drug addictions. To date CITA has grown its business through internal expansion and now seeks compatible, leading, and complementing technologies and acquisitions to enhance its corporate portfolio. CITA Biomedical, Inc. has two operating divisions CITA Americas, Inc., and AltTPro, Inc. For more information, please visit www.citabio.com .



Gruß spirity

[morchel]

Spirity,
CITA kannst du nur direkt in New York kaufen. Ist aber mit jeder Bank möglich!

Die Frage bei CITA ist, wie bei vielen anderen, die Zulassung!

Wirds von der FDA zugelassen!

morchel

[morchel]

Leading Chemical Dependency Recovery Center to Offer CITA Biomedical`s Groundbreaking Treatments for Alcohol, Cocaine, and Crack Dependence

San Pedro Hospital`s Peninsula Chemical Dependency Recovery Center to Begin
Treating Patients in Early October 2002

BEVERLY HILLS, Calif., Oct. 4 /PRNewswire-FirstCall/ --
CITA Biomedical, Inc. (OTC Bulletin Board: DTOX) a growing leader in the
treatment of addiction dependency, today announced that it has reached an
agreement with Little Company of Mary-San Pedro Hospital (LCM-SPH) in Los
Angeles County, California to provide CITA`s Detoxification and
NeuroAdaptation (DNA) for Addictions family of treatments.
(Photo: http://www.newscom.com/cgi-bin/prnh/19990413/LAPHOTO )
The San Pedro Hospital`s Peninsula Recovery Center will start treating
patients with DNA for Addictions in early October. The DNA for Addictions
treatment family includes DNA for Alcohol, DNA for Alcohol and Cocaine, DNA
for Cocaine, and DNA for Crack Cocaine. CITA has patents pending for the
family of DNA treatments.
"We are pleased to add the DNA treatments as an option for our patients
suffering from substance dependency," said Dr. Crescenzo Pisano, Medical
Director of LCM-SPH Peninsula Recovery Center. "The DNA technology now allows
us to treat addiction at the source, providing renewed hope for those who were
previously unresponsive to former treatment attempts. The combination of
CITA`s treatments and our recovery services provides our community with the
most advanced and effective treatment options available, safely administered
by our specially-trained medical professionals."
Addiction is a brain disease/disorder and DNA for Addictions treats
addiction at the source. Historically the disease of addiction has been
treated through behavioral intervention, but DNA for Addictions treatments
provide a solution for treating the physiological and psychological components
of this devastating condition. Substance abuse impedes normal neural
functioning of the brain and body systems as a whole; resulting in cravings,
potentially serious or even life-threatening withdrawal symptoms, and damage
to the brain. The CITA DNA treatment reduces or eliminates cravings while
correcting and regulating the neural functioning.
By providing successful detoxification and neural adaptation solutions
that reduce the time, severity, pain and cost associated with withdrawal, the
DNA for Addictions process allows the patient to concentrate on returning to a
productive level of functioning in a very short time. DNA for Addictions
treatments occur over two to three days, depending on the addiction(s) being
treated. The process is performed under medical supervision followed by a
continuing care program.
Completion rates for the DNA treatment process far exceed standard
detoxification solutions, approaching a 100% completion rate. DNA for
Addictions treatments have a relapse rate of less than 25%, in contrast with a
relapse rate exceeding 75% for those people treated by other methods.
"By working together, CITA, LCM-SPH, and its highly competent medical
staff are able to offer high-quality, safe, and cost-effective substance
dependence recovery services," said Joseph Dunn, president and CEO of CITA
Biomedical. "CITA`s mission is to make the transition from substance
dependence to independence as quick, smooth and humane as possible. With DNA
for Addictions we`ve done that. We plan to continue to partner with leading
treatment centers in order to make the DNA for Addictions treatment family
widely available across the U.S. and Canada."

About CITA Biomedical, Inc.
CITA Biomedical, Inc., headquartered in Beverly Hills, Calif., focuses on
the innovative treatment of addiction. The company holds the U.S. patent for
its successful UROD (Ultra Rapid Opiate Detoxification) treatment method.
UROD is the only clinically tested and effective treatment method to rapidly
detoxify individuals addicted to opiate-based drugs, including heroin, within
four to six hours with few, if any, withdrawal symptoms. The company has a new
family of revolutionary treatments, Detoxification and NeuroAdaptation (DNA)
for Addictions. The first treatments from this family treat alcohol, cocaine,
crack cocaine, and poly-drug addictions. To date, CITA has grown its business
through internal expansion and now seeks compatible, leading, and
complementing technologies and acquisitions to enhance its corporate
portfolio. CITA Biomedical, Inc. has two operating divisions CITA Americas,
Inc., and AltTPro, Inc. For more information, please visit http://www.citabio.com.

About Little Company of Mary San Pedro Hospital
Little Company of Mary San Pedro Hospital is affiliated with Little
Company of Mary Health Services. Little Company of Mary is an integrated,
regional health care system serving communities in the South Bay area of
Southern California comprised of more than 30 different medical and health
care facilities and services, including Little Company Of Mary
Hospital-Torrance and Little Company of Mary-San Pedro Hospital.
Little Company of Mary is a member of the Providence Health System.
Providence Health System operates 20 acute care hospitals, 9 freestanding
long-term care facilities, and 15 low-income and assisted living facilities.
Providence Health System extends its mission of caring and commitment across a
four-state area -- Alaska, Washington, Oregon, and Southern California. A
comprehensive array of services is available to meet the varied needs of
communities. These include acute and primary care, outpatient services,
transitional care, home and hospice care, substance abuse programs, mental
health treatment, comprehensive outreach programs including prevention and
wellness, long-term care, and housing.

NOTE: UROD is a registered trademark of CITA Biomedical, Inc.

The information contained in this press release includes forward-looking
statements. Forward-looking statements include declarations concerning plans,
objectives, goals, strategies, future events and/or performance, and
underlying assumptions and other statements which are other than statements of
historical facts. Forward-looking statements usually contain the words
"estimate," "anticipate," "believe," "expect" and other similar expressions
that involve risks and uncertainties. These risks and uncertainties include,
but are not limited to, the Company`s status as a start-up enterprise with
uncertain profitability, its need for significant capital, limited facilities,
competition, uncertainty as to market acceptance of its services, and the
protection of its intellectual property. The Company`s actual results could
differ materially from those expressed or implied in any forward-looking
statements.

Contacts: Investor Relations Treatment Information
CITA Biomedical, Inc. Call: 1-888-400-2482
Judy Ryon, 310-550-4971 or
[e-mail] Visit: http://www.cita1.com

morchel

[loss_pro]

die fallen auch immer weiter

[morchel]

ja, leider...obwohl ich die Story interessant finde!

bin aber noch nicht in die Tiefe gegangen und hab auch keinen Kontakt zum Management!

morchel